Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
356 participants
INTERVENTIONAL
2004-10-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
NCT00413023
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
NCT00048204
An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
NCT00057226
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
NCT00057213
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
NCT00057239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW679769
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must have met DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) criteria for current MDE (major depressive episode) for at least 8 weeks prior to the Screening Visit.
* If female, subjects must be practicing an acceptable method of birth control.
* Subjects must have rating scores as outlined.
Exclusion Criteria
* Subjects with a history of schizophrenia, schizoaffective disorders or bipolar disorder.
* Subjects have a positive urine test for illicit drug use and/or a history of substance abuse or alcohol dependence within the past 12 months.
* Subjects with an unstable medical disorder.
* If female, pregnant or lactating.
* Subjects who have received ECT (electroconvulsive therapy) or TMS (transcranial magnetic stimulation) within the 6 months preceding screening or who have ever been homicidal.
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
North Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Winter Park, Florida, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Smyrna, Georgia, United States
GSK Investigational Site
Oakbrook Terrace, Illinois, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Rockville, Maryland, United States
GSK Investigational Site
Farmington Hills, Michigan, United States
GSK Investigational Site
Saint Charles, Missouri, United States
GSK Investigational Site
Clementon, New Jersey, United States
GSK Investigational Site
Brooklyn, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Beachwood, Ohio, United States
GSK Investigational Site
Eugene, Oregon, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Memphis, Tennessee, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Irving, Texas, United States
GSK Investigational Site
Lake Jackson, Texas, United States
GSK Investigational Site
Bellevue, Washington, United States
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Miramichi, New Brunswick, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKF100092
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.